BioMarin Pharmaceutical Inc. (BMRN) Q1 2012 Earnings Results

BioMarin Pharmaceuticals Misses on EPS — Stock Down 0.51%

BioMarin's earnings report showed a significant miss on EPS, which likely contributed to the slight decline in stock price. Investors may be concerned about the lack of revenue details and future guidance. The management's defensive tone suggests they are aware of the challenges ahead, particularly in their product pipeline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.21	N/A	-44.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over recent performance but highlighted ongoing efforts in product development. They did not provide any updates on future guidance.

Management acknowledged the challenges faced in the quarter.

They emphasized the need for continued focus on pipeline development.

There was no specific guidance provided for future quarters.

BioMarin Pharmaceuticals Misses on EPS — Stock Down 0.51%

Key numbers

Management commentary

BioMarin Pharmaceutical Inc.

More earnings this week

BioMarin Pharmaceuticals Misses on EPS — Stock Down 0.51%

Key numbers

Management commentary